VJHemOnc Podcast

The evolving treatment landscape in ALL: the growing role of immunotherapy and reduced reliance on chemotherapy

There has been a significant shift in the treatment of acute lymphoblastic leukemia (ALL), driven by the emergence of novel immunotherapies. In this episode, leading experts explore how these advances are changing the tr

Precision medicine in MDS: tailoring treatment through molecular profiling

This VJHemOnc podcast explores how precision medicine is reshaping the management of myelodysplastic syndromes (MDS). Alex Bataller, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses whol

The current and future role of BTK inhibitors across non-Hodgkin lymphoma subtypes

This episode of the VJHemOnc podcast explores the current and future role of BTK inhibition across several non-Hodgkin lymphoma (NHL) subtypes. First, Charalampia Kyriakou, MD, PhD, University College London Hospitals NH

The diagnosis and management of hematologic malignancies during pregnancy

In this episode of the VJHemOnc podcast, Daan Dierickx, MD, PhD, KU Leuven and University Hospitals Leuven, Leuven, Belgium, shares insight into the diagnosis and management of hematologic malignancies during pregnancy.

Hodgkin lymphoma in 2026: frontline strategies, ctDNA, and treatment after relapse

This VJHemOnc podcast explores the latest advances in Hodgkin lymphoma, from evolving frontline treatment strategies to emerging approaches in relapsed and refractory disease. Graham Collins, MA, MBBS, MRCP, FRCPath, DPh

Sequencing BTK inhibitor therapy in CLL: treatment considerations and emerging strategies

This podcast explores sequencing strategies and treatment considerations for BTK inhibitors in chronic lymphocytic leukemia (CLL). Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses treatment op

Precision medicine in AML: from targeted therapy to transplantation

This podcast explores the evolving role of precision medicine in acute myeloid leukemia (AML), highlighting advances in molecular profiling, targeted therapies, measurable residual disease (MRD) assessment, and transplan

MPNs in focus: disease progression, risk assessment, and emerging treatments

This VJHemOnc podcast explores how advances in disease biology, risk stratification, and therapeutic development are reshaping the management of myeloproliferative neoplasms (MPNs). Stephen Oh, MD, PhD, Washington Univer

The evolving role of cellular therapies and T-cell engagers in lymphoma

This VJHemOnc podcast explores emerging cellular therapies and T-cell engagers in non-Hodgkin lymphoma (NHL). Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, is joined by Paolo Strati, MD, The University

Multiple myeloma in 2026: MRD, BCMA therapies, CAR-T, and the path to cure

This VJHemOnc podcast explores how evolving treatment strategies, immunotherapies, and MRD-driven approaches are reshaping the management of multiple myeloma and precursor disease. Irene Ghobrial, MD, Dana-Farber Cancer

Dual-targeting CAR T-cell therapies in LBCL: efficacy, safety, and bridging therapy

This VJHemOnc podcast features a roundtable discussion from the 8th International Workshop on CAR-T and Bispecifics (iwCAR-T) 2026 on the evolving role of dual-targeting CAR T-cell therapies in large B-cell lymphoma (LBC

Advances in gene-based therapies for SCD and thalassemia: access, outcomes & innovation

This VJHemOnc podcast explores the latest advances in gene-based therapies for sickle cell disease (SCD) and thalassemia, highlighting progress in patient access, selection, treatment delivery, and clinical outcomes. Sun

The evolving role of BTK inhibitors in CLL

Adverse events in the post-CAR T-cell therapy setting: infections, less common toxicities, and advice for physicians

In this episode of the podcast, we focus on adverse events (AEs) and toxicities in the post-CAR T-cell therapy setting. First, Marion Subklewe, MD, Ludwig Maximilians University of Munich, Munich, Germany, outlines the m

The evolving treatment landscape in MCL: chemo-free strategies, BTK inhibitors, and changing standards of care

This VJHemOnc episode explores major shifts in frontline mantle cell lymphoma (MCL) care, highlighting the move from traditional chemotherapy to chemo‑free regimens and the growing role of BTK inhibitors. Michael Wang, M

Advances in stem cell transplantation from EBMT 2026: managing GvHD, donor selection & evolving clinical strategies

This episode reviews major advances presented at the EBMT 2026 meeting in Madrid, covering novel treatments for acute and chronic GVHD, including a promising microbiome-based therapy, and new targeted agents. Experts dis

Myeloid Monthly: breaking news & updates from the classification advancement meeting

This VJHemOnc podcast introduces the first edition of Myeloid Monthly, focusing on key developments in myeloid malignancies. Amer Zeidan, MD, Yale University, New Haven, CT, is joined by Robert Hasserjian, MD, Massachuse

How AI is transforming hematologic oncology

This VJHemOnc podcast explores how artificial intelligence (AI) is transforming hematologic oncology, from clinical research and diagnostics to risk prediction and therapy development. Aaron Gerds, MD, Cleveland Clinic,

MRD in ALL and AML: from prognostic marker to clinical endpoint

This VJHemOnc podcast explores the evolving role of measurable residual disease (MRD) in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), from prognostic marker to clinical endpoint. Harry Erba, MD, P

Nursing in CAR-T & cellular therapy: updates and insights from the EBMT-EHA CAR T-cell Meeting 2026

Nurses play a key role in the CAR T-cell therapy process. In this podcast episode, you will hear insights into nursing in CAR-T and cellular therapy through exclusive interviews from the recent EBMT-EHA 8th European CAR